InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001883850-23-000091 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-12-12 2023-12-08 REGN Van Plew Daniel P EVP, General Mgr, Industrial A - Grant $0.00 +3,199 23.6K +16% $0
DM 2023-12-12 2023-12-08+ REGN Van Plew Daniel P EVP, General Mgr, Industrial F - Tax $844.01 -4,329 20.4K -18% -$3.65M
D 2023-12-12 2023-12-08 REGN Van Plew Daniel P EVP, General Mgr, Industrial A - Grant $0.00 +11.5K 11.5K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-12-08 A A 3,199 $0.00 23,599 D — —
2 Common Common Stock 2023-12-11 F D 669 $844.09 20,378 D — —
3 Common Common Stock 2023-12-11 F D 2,552 $844.09 21,047 D — —
4 Common Common Stock 2023-12-08 F D 1,108 $843.79 20,400 D — —
5 Derivative Non-Qualified Stock Option (right to buy) 2023-12-08 A A 11,473 $0.00 11,473 D $843.79 · — to 2033-12-08 11,473 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.